If you're on Medicare here in the Midlands and you've been wondering whether your drug plan will help pay for one of these GLP-1 medications, you're asking exactly the right question. The answer used to be a flat no for weight loss. As of 2026, it's more complicated, and in some cases the answer is finally yes. Here's the straight version.

The short answer: it depends on why it's prescribed

Medicare Part D doesn't decide coverage based on the drug alone. It decides based on the medical reason your doctor writes on the prescription. The very same medication can be covered or denied depending on your diagnosis. That one fact explains almost everything about GLP-1 coverage, so keep it in mind as you read.

Covered for Type 2 diabetes

If you have Type 2 diabetes, you're in the strongest position. Part D plans in South Carolina cover Ozempic and Mounjaro when they're prescribed to manage diabetes, because that's what they're FDA-approved to do. Ozempic can also be covered in some cases for kidney or cardiovascular reasons. Your exact cost depends on your plan's formulary tier, and many plans require prior authorization or step therapy first, but the coverage is there.

What Part D will not do is cover Ozempic or Mounjaro for weight loss. If the prescription says weight loss and you don't have diabetes, expect a denial under standard Part D.

Covered for a related condition

Here's where it gets interesting. Some of these drugs are now covered when you have a specific condition beyond diabetes:

• Wegovy can be covered under Part D for people with established cardiovascular disease who are overweight or obese, following an FDA label change. It's the heart-risk indication, not weight loss by itself, that opens the door.
• Zepbound can be covered when it's prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity.

If either of those fits your situation, it's worth having your doctor note the qualifying diagnosis, because it can change your coverage entirely.

The big change for 2026: the Medicare GLP-1 Bridge program

For years, the door was simply closed if you wanted one of these drugs purely to lose weight. That changed on July 1, 2026, when Medicare launched a temporary program called the GLP-1 Bridge. It runs through the end of 2027, and it's the first time Medicare has helped pay for these medications for weight loss alone.

Here's how it works:

• What's covered: Wegovy (injection or tablet), the Zepbound KwikPen, and Foundayo. Note that the single-dose Zepbound pen and Zepbound vials are not included.
• What it costs: a flat $50 per month for a 30-day supply, no matter your income, and the copay doesn't climb as your dose increases.
• Who qualifies: you need to be enrolled in a participating Part D plan and meet the clinical criteria — generally a BMI of 35 or higher, or a BMI of 27 or higher paired with a condition like cardiovascular disease, prediabetes, or high blood pressure.

The catches worth knowing before you count on it

The Bridge program is real help, but it isn't automatic, and a few details trip people up:

• Not every Part D plan participates. It has to be a qualifying plan, so your specific plan matters.
• Prior authorization is required, and it goes to a central Medicare processor rather than your usual plan — a new system that can mean delays if your doctor's office hasn't done one yet.
• The $50 copays don't count toward your Part D deductible or the $2,100 annual out-of-pocket cap, because the program runs outside normal Part D.
• It's temporary. The program is scheduled to end December 31, 2027, so it's a bridge, not a permanent fix.

Does your South Carolina plan cover it?

This is the part I can actually answer for you, because it comes down to your specific plan and your specific medication. Two neighbors on two different Part D plans can get two completely different answers, and the only way to know yours is to check your plan's formulary and its rules.

Check your medication in about 60 seconds. Run your drug through our free Rx Drug Lookup. We'll tell you whether your plan covers it, what your real out-of-pocket cost will be, whether prior authorization applies, and whether switching plans during open enrollment would save you money. There's no charge and no obligation.

The bottom line

Whether Medicare Part D covers Ozempic, Wegovy, or Zepbound comes down to your diagnosis, your plan, and — for weight loss specifically — whether you qualify for the new GLP-1 Bridge program. The rules are shifting fast, and the plans vary more than most people expect. Before you assume you're covered or assume you're not, get a clear answer for your situation.

Ready for that answer? Use our Rx Drug Lookup or call Mauldin Insurance Group. We help Lexington and Midlands seniors sort out exactly this, at no cost, every day.

This article is for general information and isn't medical or plan-specific advice. Coverage rules change and vary by plan; confirm your own benefits before making decisions about your medications or your Medicare coverage.